@tomchena I wouldn't say it's a question mark as much as it's perhaps not as imminent as some may have expected. But I for one am pleased that the reason they've not achieved cash flow positivity or more of a move towards profitability in this quarter is largely due to a significant increase in production costs. As stated, they are ramping up production to increase inventory and meet the emerging demand, and this goes a long way to quelling my primary fear for the retail side, which was that of over-trading.
Ally that to the quiet confidence on midkine, and this has all the hallmarks of a very strong year on the horizon, IMO. DYOR
- Forums
- ASX - By Stock
- AN1
- Ann: Appendix 4C and Notes to Appendix 4C
Ann: Appendix 4C and Notes to Appendix 4C, page-7
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online